FierceBiotechOriginal article
{"a":[{"_":"Zydus’ Sentynl pens $475M deal for Mereo’s phase 3-ready rare genetic lung disease drug","$":{"href":"/biotech/mereo-springs-475m-biobucks-sentynl-phase-3-ready-rare-genetic-lung-disease-drug","hreflang":"en"}}]}
PartnershipPositive
AI Analysis
Summary
Sentynl Therapeutics has entered into a deal worth up to $475 million to license the option to market Mereo BioPharma's phase 3-ready rare genetic respiratory disease drug in the U.S.
Clinical Trial Data
Phase
Phase 3
Importance:7/10
Sentiment:
0.60
partnershiplicensingrare diseasephase 3M&A
Related Companies
Read the original article
Published by FierceBiotech on August 11, 2026 9:38 AM